^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Gallbladder Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    World J Surg Oncol
    Title:

    Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature

    Published date:
    07/04/2020
    Excerpt:
    ...erlotinib in combination with gemcitabine and oxaliplatin in treating an EGFR-mutated GBC with liver metastasis…showing a complete radiological response... has not shown any further disease progression 11 months after initiation of treatment.
    Secondary therapy:
    gemcitabine + oxaliplatin
    DOI:
    10.1186/s12957-020-01934-4